On 21 November 2018, the European Brain Council, together with its industry partners, will host the event “Enhanced engagement through public-private partnerships: Sustaining therapeutic innovation to address patient needs” as part of its Value of Innovation series.

The full day event will provide the opportunity for individual EBC members and industry partners to showcase their latest initiatives to the broader EBC membership and other key stakeholders including the European Parliament & Commission, highlighting collaboration, innovation and multi-stakeholder engagement. Built around a number of keynote speeches, presentations and poster presentations, the aim for the day is to create a forum and foster dialogue focused on improving outcomes for patients in 3 key areas – Research & Development in Brain Health, Patient Engagement and Disease Awareness.

The full agenda can be found below. Keynotes will be delivered by Ms Sohini Chowdhury (Deputy CEO, The Michael J. Fox Foundation for Parkinson’s Research) and Prof. Guendalina Graffigna (Universita’ Cattolica Milan), with chairs Dr. Pierre Meulien (Director, Innovative Medicines Initiative – IMI), Mr Andrew Powrie-Smith (Executive Director of Communications & Partnerships, EFPIA) and EBC executives. The day will be divided into Keynote lectures, presentation sessions, an interactive breakout session and a lunchtime poster session.

Breakout sessions will give participants the opportunity to engage and collaborate on a number of topics, including how industry and EBC stakeholders should collaborate to advance and accelerate access to major medical breakthroughs in CNS conditions and enhance the speed of translation of science to clinical application as well as how Industry and EBC stakeholders should enhance partnerships to improve patient engagement in their conditions.

The anticipated outcomes of the day will be to create a debate that will generate a nucleus of ideas that describe how public-private partnerships and multi-stakeholder engagement  can improve outcomes for patients with Brain conditions across the three prescribed areas of focus.